– Exponent, a leading European private equity firm, has announced the final close of its fifth fund, Exponent Private Equity Partners V (“Fund V”), at £900 million (over €1 billion), which is 20% above its target.
– Fund V received strong support from a globally diversified investor base, including:
▪️Longstanding partners and new investors from North America, Europe, the Middle East, and Asia
▪️Pension funds, endowments, sovereign wealth funds, family offices, and other institutional investors
– The fund continues Exponent’s mid-market investment strategy, targeting:
▪️Corporate, family, and founder-owned businesses of scale
▪️Companies that are market leaders and primaries (first-time institutional capital)
▪️Focus on doubling profits through revenue-driven growth levers
– Marius Østlie, Partner: Highlighted strong LP conviction in Exponent’s team, strategy, and track record, and welcomed new investors.
– Richard Lenane, Managing Partner: Emphasized Exponent’s differentiated mid-market strategy, delivering value across economic cycles with sub-sector expertise and operational discipline.
– Fund V has already made four investments:
▪️Chanelle Pharma – European leader in generic and veterinary pharmaceuticals
▪️Ethos Engineering – Specialist in sustainable data centre design
▪️Kingsbridge Healthcare Group – Largest private healthcare provider in Northern Ireland, with operations also in the Republic of Ireland
▪️Hippo Digital – Technology consultancy focused on user-centred digital transformation
